scholarly journals Spontaneous granulocytic leukemia in a NOD/Shi-scid IL-2Rγnull mouse

Author(s):  
Hirotoshi AKANE ◽  
Sumiko OKUDA ◽  
Yasuaki OISHI ◽  
Atsuko ICHIKAWA ◽  
Hajime TABATA
Cancer ◽  
1986 ◽  
Vol 58 (2) ◽  
pp. 229-233 ◽  
Author(s):  
Alessandro Levis ◽  
Filippo Marmont ◽  
Maria A. Ciocca Vasino ◽  
Augusto Jayme ◽  
Vittorio Infelise ◽  
...  

1998 ◽  
Vol 30 (3-4) ◽  
pp. 293-306 ◽  
Author(s):  
ZoltÁN Beck ◽  
Attila Bácsi ◽  
Eszter Kovács ◽  
JolÁN Kiss ◽  
Attila Kiss ◽  
...  

2021 ◽  
Vol 7 (5) ◽  
pp. 3150-3154
Author(s):  
GeLe Tong ◽  
Liusha Xu ◽  
Yanqi Leng ◽  
Pang Wu

Objective: To investigate the clinical effect of granulocyte colony-stimulating factor combined with erythropoietin on chronic granulocytic leukemia with anemia and its effect on nutritional status. Methods: 60 patients of chronic granulocytic leukemia of our hospital with anemia induced by maintenance chemotherapy were randomly divided into two groups. Patients in the control group received routine treatment, while patients in the observation group received basal treatment with granulocyte colony-stimulating factor and erythropoietin. The nutritional status before and after treatment as well as the immune function and the incidence of blood transfusion and adverse events were compared between the two groups. Results: There was no significant difference in hemoglobin, hematocrit, nutritional status and immune function between the two groups before treatment (P>0.05). Those after treatment were significantly higher than that before treatment (P<0.05). After treatment, the percentage of CD4* cells in the control group was significantly higher than that before treatment (P<0.05), but the percentage of CD8* cells and CD47/CD8* cells did not change significantly (P>0.05). After treatment, the concentrations of IgA, IgM and IgG in the observation group were significantly higher than those before treatment (P<0.05), but only the concentrations of IgA and IgM in the control group were significantly higher than those in the observation group after treatment (P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group. Conclusion: Granulocyte colony-stimulating factor combined with erythropoietin can effectively correct anemia, improve nutritional status and improve immune function in patients with chronic myelogenous leukemia.


Sign in / Sign up

Export Citation Format

Share Document